The chemotherapy induced neutropenia market is expected to grow at a CAGR of 4.3% during 2025–2034. This growth is driven by the rising prevalence of cancer and increasing demand for effective neutropenia management solutions across the 8 major markets, aimed at improving patient outcomes and reducing complications associated with chemotherapy treatments. https://www.expertmarketresearch.com/reports/chemotherapy-induced-neutropenia-market